Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(6 Suppl):1–158.

Abbonizio F, Biffoni M, Arcieri R, Associazione Italiana Centri Emofilia (AICE), Giampaolo A. Rapporti ISTISAN 22/38 [in Italian]. National registry of congenital bleeding disorders. Report 2020. 2022. https://www.iss.it/-/rappporto-istisan-22/38-registro-nazionale-coagulopatie-congenite.-rapporto-2020.-francesca-abbonizio-mauro-biffoni-romano-arcieri-associazione-italiana-centri-emofilia-aice-adele-giampaolo. Accessed September 2023.

Castaman G, Linari S. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks. Expert Rev Hematol. 2018;11(7):567–76.

Article  CAS  PubMed  Google Scholar 

Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia. 2016;22(3):381–8.

Article  CAS  PubMed  Google Scholar 

Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11(8):673–83.

Article  CAS  PubMed  Google Scholar 

Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 2014;20(3):398–406.

Article  CAS  PubMed  Google Scholar 

Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–23.

Article  CAS  PubMed  Google Scholar 

Berntorp E, Spotts G, Patrone L, Ewenstein BM. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics. 2014;8:115–27.

PubMed  PubMed Central  Google Scholar 

Fischer K, Grobbee DE, van den Berg HM. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. Haemophilia. 2007;13(4):345–50.

Article  CAS  PubMed  Google Scholar 

Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44.

Article  CAS  PubMed  Google Scholar 

Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020;4(11):2451–9.

Article  PubMed  PubMed Central  Google Scholar 

Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011(9):CD003429.

Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014;12(4):575–98.

PubMed  PubMed Central  Google Scholar 

Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186–92.

Article  PubMed  PubMed Central  Google Scholar 

Malec LM, Cheng D, Witmer CM, et al. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020;95(8):960–5.

Article  PubMed  Google Scholar 

Burke T, Asghar S, O’Hara J, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US+ population surveys. Orphanet J Rare Dis. 2021;16(1):143.

Article  PubMed  PubMed Central  Google Scholar 

Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med. 2017;6(4):39.

Article  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. BeneFIX® Summary of Product Characteristics. 2012. https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf. Accessed July 2023.

European Medicines Agency. Alprolix® Summary of Product Characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf. Accessed July 2023.

Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600–6.

Article  CAS  PubMed  Google Scholar 

Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105(2):518–25.

Article  CAS  PubMed  Google Scholar 

Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4(2):e75–82.

Article  PubMed  Google Scholar 

Nolan B, Klukowska A, Shapiro A, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Adv. 2021;5(13):2732–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Funding E, Lowe G, Poulsen LH, et al. Real-world effectiveness of rFIXFc prophylaxis in patients with haemophilia B switched from standard half-life therapy in three European countries. Adv Ther. 2023;40(9):3770–83.

Article  PubMed  PubMed Central  Google Scholar 

Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262–71.

Article  CAS  PubMed  Google Scholar 

Astermark J, Hermans C, Ezzalfani M, et al. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires. Haemophilia. 2022;28(1):18–26.

Article  CAS  PubMed  Google Scholar 

Astermark J, Hermans C, Ezzalfani M, et al. Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes. Ther Adv Hematol. 2023;14:20406207231170700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wyrwich KW, Krishnan S, Auguste P, et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016;22(6):866–72.

Article  CAS  PubMed  Google Scholar 

Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437–43.

Article  CAS  PubMed  Google Scholar 

Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics. 2002;20(11):759–74.

Article  PubMed  Google Scholar 

Zhou ZY, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18(6):457–65.

Article  PubMed  Google Scholar 

Witmer C, Pressley R, Kulkarni R, Soucie JM, Manno CS. Intracranial hemorrhage in patients with hemophilia in the prophylaxis era. Blood. 2008;112(11):3388.

Article  Google Scholar 

Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13(3):233–43.

Article  CAS  PubMed  Google Scholar 

Shrestha A, Eldar-Lissai A, Hou N, Lakdawalla DN, Batt K. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267–75.

Article  CAS  PubMed  Google Scholar 

Chowdary P, Dasani H, Jones JA, et al. Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia. 2001;7(2):140–5.

Article  CAS  PubMed  Google Scholar 

Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nolan B, Mahlangu J, Pabinger I, et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study. Haemophilia. 2020;26(3):494–502.

Article  CAS  PubMed  PubMed Central